All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The phase II randomized SORAML trial assessed the efficacy of sorafenib, a multi-targeted kinase inhibitor, in combination with standard chemotherapy in newly diagnosed patients with AML aged ≤60 years. In total, 267 AML patients (median age = 50 years) were randomly assigned to receive standard induction and post-remission chemotherapy with (n = 134) or without sorafenib (n = 133). The primary endpoint of the study was Event Free Survival (EFS).
Findings from that study after a median follow-up of 3 years showed that sorafenib in combination with standard induction and consolidation therapy significantly prolonged the EFS and Relapse Free Survival (RFS) in patients. However, although the Overall Survival (OS) was higher in patients administered sorafenib, it was not statistically significant.1
Christoph Röllig, MD, from University Hospital, Dresden, Germany, presented an updated results from the long-term follow up of outcomes in patients treated in the phase II randomized SORAML trial (NCT00893373) during an oral abstract session at the 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, on Monday 11th December 2017.2
The speaker concluded that, the long-term follow up analysis of this SORAML trial “confirms significant prolongation of EFS by addition of sorafenib to standard chemotherapy” in newly diagnosed AML patients irrespective of their FLT3 mutation status.
Primary sorafenib led to a better OS compared to placebo, albeit not significantly, which the speaker concluded is probably a result of the fact that this “phase II trial was not adequately powered to detect OS differences”.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox